Neurothera Labs (FRA:C0A) EBIT: €-0.14 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C0A Neurothera Labs Inc FRA:C0A
32 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs EBIT?

Neurothera Labs FRA:C0A +0.34% 32 EBIT is €-0.14 Mil as of Dec. 2025. GuruFocus rates FRA:C0A with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Neurothera Labs's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.14 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Neurothera Labs's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. Neurothera Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Neurothera Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -0.80%.

Neurothera Labs  (FRA:C0A) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Neurothera Labs's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - 0% )/( (0 + 1.597)/ 2 )
=0/0.7985
=0.00 %

where

Invested Capital(Q: Jul. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.65 - 0.097 - ( 0.649 - max(0, 0.097 - 0.65+0.649))
=0

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.59 - 0.579 - ( 1.453 - max(0, 1.177 - 1.591+1.453))
=1.597

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Neurothera Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jul. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (0 + max(-0.096, 0)) + (0 + max(-0.792, 0)) )/ 2 )
=0/( ( 0 + 0 )/ 2 )
=0/0
= %

where Working Capital is:

Working Capital(Q: Jul. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0 + 0) - (0.097 + 0 + 0)
=-0.096

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.009 + 0.064 + 0.0079999999999998) - (0.579 + 0 + 0.294)
=-0.792

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Neurothera Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-0.135/16.926
=-0.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs EBIT Related Terms

Neurothera Labs EBIT Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs EBIT Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
EBIT
-0.00 -0.10 -0.06 -0.07 -0.17

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.10 -0.01 -0.01 0.00

FRA:C0A vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Neurothera Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurothera Labs EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neurothera Labs's EV-to-EBIT falls into.


FRA:C0A
32GF Score
Neurothera Labs Inc FRA:C0A
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-0.14 Mil mean?
Neurothera Labs (FRA:C0A) has a EBIT of €-0.14 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neurothera Labs.
Is Neurothera Labs' EBIT too high?
Neurothera Labs' current EBIT is €-0.14 Mil. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' EBIT compare to LLY and JNJ?
Neurothera Labs' EBIT of €-0.14 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neurothera Labs. Neurothera Labs's current EBIT is €-0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (FRA:C0A) has a current EBIT of €-0.14 Mil. The current EBIT is €-0.14 Mil. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Neurothera Labs (FRA:C0A), the current EBIT is €-0.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurothera Labs Business Description

Other Exchanges NTLX:Canada
Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score

Get the complete analysis for FRA:C0A

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price